Eupraxia Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Rhea-AI Summary

Eupraxia Pharmaceuticals (NASDAQ/TSX: EPRX) reported Q4 2024 financial results, highlighting positive developments in its clinical trials. The company posted a net loss of $7.5 million for Q4 2024, an improvement from the $10.6 million loss in Q4 2023. Cash position strengthened to $33.1 million as of December 31, 2024, up from $19.3 million year-over-year.

Key highlights include compelling data from the Phase 1b/2a RESOLVE trial for EP-104GI in treating eosinophilic esophagitis, with improved tissue health and symptom reduction outcomes at higher doses. The company successfully raised C$44.5 million through a private placement, extending its funding runway into Q3 2026.

The company is monitoring potential impacts of proposed 25% U.S. tariffs on Canadian goods and planned Canadian retaliatory tariffs, as it sources API and manufactures clinical supplies in the U.S.

Positive

• Net loss decreased by $3.1 million year-over-year in Q4 2024
• Cash position increased to $33.1 million from $19.3 million YoY
• Successful C$44.5 million private placement strengthening balance sheet
• Positive clinical trial results for EP-104GI with no adverse events

Negative

• Continued net loss of $7.5 million in Q4 2024
• Potential exposure to 25% tariffs on U.S.-Canada trade

Insights

Financial Analyst

Eupraxia's Q4 2024 results demonstrate improved financial efficiency with net losses decreasing to $7.5 million from $10.6 million in Q4 2023. The company has substantially strengthened its balance sheet, ending with $33.1 million in cash (up from $19.3 million year-over-year) following a significant C$44.5 million private placement in October.

The termination of their C$12 million convertible debt facility simplifies the capital structure and reduces potential future dilution. Management projects runway extension into Q3 2026, providing approximately 18 months of operational capability without additional financing – a critical metric for clinical-stage biotechs where cash burn rate directly impacts development timeline feasibility.

While the company continues to operate at a loss as expected for a clinical-stage biotech, the 31% year-over-year reduction in quarterly net loss indicates prudent financial management. With 35.6 million common shares and 8.9 million preferred shares outstanding, the company has preserved adequate financing flexibility while extending its operational timeline. Their proactive currency management strategy, maintaining USD balances to hedge against exchange fluctuations, demonstrates foresight regarding potential US-Canada trade tensions.

Biotech Research Specialist

Eupraxia's clinical data from their RESOLVE trial shows a promising dose-response relationship for EP-104GI in eosinophilic esophagitis (EoE), with higher doses correlating to improvements in both tissue health markers and symptom reduction. The sixth cohort data released in February 2025 confirms this pattern with no reported adverse events – suggesting a potentially favorable safety profile at therapeutic doses.

The external validation of their research is particularly noteworthy. Their Phase 2b SPRINGBOARD trial for knee osteoarthritis gained publication in The Lancet Rheumatology, one of the field's most selective journals with rigorous peer review. Additionally, their EoE research earned a Presidential Award at the American College of Gastroenterology meeting, signifying recognition from the scientific community for novel, high-quality research.

Their DiffuSphere™ technology platform, designed for optimized drug delivery, appears to be demonstrating real-world clinical benefits across multiple conditions – from osteoarthritis to EoE. This suggests platform versatility that could potentially be leveraged across additional indications. The continued positive data emerging from higher dosing cohorts indicates they're still determining optimal therapeutic parameters, but the consistent safety profile across increasing doses provides confidence in their approach to dose escalation while pursuing enhanced efficacy.

VICTORIA, BC, March 20, 2025 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize drug delivery for applications with significant unmet need, today announced its financial results for the fourth quarter of 2024. All dollar values are in U.S. dollars unless stated otherwise.

"During the fourth quarter of 2024, and again in the current quarter of 2025, we delivered compelling data from our Phase 1b/2a RESOLVE trial for EP-104GI as a potential treatment for eosinophilic esophagitis," said Dr. James Helliwell, Chief Executive Officer of Eupraxia. "The results from the first six cohorts of the trial show that precise, localized delivery of EP-104GI at higher doses is leading to further improvements in tissue health and symptom reduction outcomes. In addition, during the fourth quarter, we raised C$44.5 million, significantly strengthening our balance sheet and ensuring the Company is well-funded into the second half of 2026."

Recent Operational and Financial Highlights

• On October 2, 2024, the Company announced the appointment of Dr. Amanda Malone as the Chief Operating and Scientific Officer of the Company.
• On October 10, 2024, the Company announced a poster presentation at the United European Gastroenterology Week 2024 featuring data from cohorts one through four of Eupraxia's ongoing RESOLVE trial in EoE.
• On October 15, 2024, the Company announced that Phase 2b data from its SPRINGBOARD trial evaluating EP-104IAR for the treatment of knee osteoarthritis was published in leading peer reviewed medical journal The Lancet Rheumatology.
• On October 28, 2024, the Company announced two poster presentations at the American College of Gastroenterology 2024 Annual Scientific Meeting centered on EP-104GI for the treatment of EoE. One poster received a Presidential Award from the conference, which is a distinction for high quality, novel, unique, and interesting research, while the other was designated an "Abstract of Interest".
• On October 31, 2024, the Company announced the closing of a non-brokered private placement for gross proceeds of C$44.5 million, the appointment of Mr. Joseph Freedman to its Board of Directors, and the termination of its C$12 million convertible debt facility.
• On November 12, 2024, the Company announced positive 12-week data from the fifth cohort of the ongoing RESOLVE trial in patients with eosinophilic esophagitis ("EoE"), noting increasingly positive data on efficacy and safety outcomes as well as emerging evidence of improved patient responses related to higher dosing levels.
• On November 14, 2024, the Company announced a poster presentation at the American College of Rheumatology Convergence 2024 Annual Meeting covering data from Eupraxia's Phase 2b SPRINGBOARD trial evaluating EP-104IAR for the treatment of knee osteoarthritis.
• Subsequent to quarter end, on February 18, 2025, the Company announced the return of seasoned capital markets executive Alex Rothwell to the role of Chief Financial Officer, succeeding the retiring Bruce Cousins.
• Subsequent to quarter end, on February 25, 2025, the Company announced positive 12-week data from the sixth cohort of the ongoing RESOLVE trial in patients with EoE noting no adverse events and continued positive data on efficacy and safety outcomes as well as further evidence of improved patient responses tied to higher dosing levels.

Fourth Quarter 2024 Financial Review

The Company incurred a net loss of $7.5 million for the three months ended December 31, 2024, versus a net loss of $10.6 million for the three months ended December 31, 2023. The decrease in net loss was primarily due to lower research and development costs and reduced other expenses incurred during the period.

The Company had cash of $33.1 million as of December 31, 2024, up from $19.3 million at the end of the fourth quarter of 2023. These funds are being used to fund clinical trials in EP-104 and the remainder of the proceeds will be used for general and administrative expenses, working capital needs and other general corporate purposes.

The Company anticipates that existing cash reserves, and anticipated proceeds from in-the-money warrants, will be sufficient to fund the Company to the third quarter of 2026.

As of December 31, 2024, the Company had 35,641,603 common shares issued and 8,905,638 preferred shares outstanding.

Potential Impact of Tariffs

Management continues to monitor the North American trade situation stemming from the February 2025 announcement by the U.S. government of proposed 25% tariffs on selected imported Canadian goods, and the subsequent Canadian announcement of planned retaliatory tariffs on selected imported U.S. goods.

Eupraxia sources its active pharmaceutical ingredient ("API") (fluticasone propionate) from the United States and clinical supplies of EP-104 IAR and EP-104GI are manufactured in the U.S. by a third-party. The Company expects to continue to access both API and manufactured products from the U.S.

The Company maintains U.S. dollar balances to pay U.S. dollar expenses and to minimize the impact of short-term fluctuations in exchange rates.

Management continues to assess the potential direct and indirect impacts of tariffs, counter-tariffs and other trade protection measures on Eupraxia's business and will take those steps it deems necessary to attempt to mitigate any impact as the situation evolves.

Financial Statements and Management Discussion & Analysis

Please see the audited consolidated financial statements and related MD&A for more details. The audited consolidated financial statements for the year ended December 31, 2024, and related MD&A, have been reviewed and approved by Eupraxia's Audit Committee and Board of Directors. For a more detailed explanation and analysis, please refer to the MD&A that has been filed under the Company's profile on EDGAR at www.sec.gov/search-filings, and on SEDAR+ at sedarplus.ca and is also available on the Company's website at www.eupraxiapharma.com.

About Eupraxia Pharmaceuticals Inc.

Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the DiffuSphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas.

Eupraxia's EP-104GI is currently in a Phase 1b/2a trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: www.eupraxiapharma.com.

Notice Regarding Forward-looking Statements and Information

This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "is expected", "expects", "suggests", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes", "potential" or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the Company's product candidates, including their expected benefits to patients with respect to safety, tolerability, efficacy and duration; the results gathered from studies and trials of Eupraxia's product candidates;  the potential for the Company's technology to impact the drug delivery process; potential market opportunity for the Company's products; potential pipeline indications; expectations regarding the funding of the Company's operations to the third quarter of 2026, and the use of cash reserves and proceeds from the exercise of warrants; and expectations regarding continued access to both API and manufactured products from the U.S., as well as ongoing monitoring and necessary actions to attempt to mitigate any impact of tariffs, counter-tariffs and other trade protection measures on the Company's business. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its products and services; the potential impact of tariffs on the cost of the Company's API and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ (sedarplus.ca) and EDGAR (sec.gov). Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/eupraxia-pharmaceuticals-reports-fourth-quarter-2024-financial-results-302407535.html

SOURCE Eupraxia Pharmaceuticals Inc.

FAQ

What were Eupraxia's (EPRX) Q4 2024 financial results?

EPRX reported a net loss of $7.5 million in Q4 2024, improved from $10.6 million loss in Q4 2023, with cash position of $33.1 million as of December 31, 2024.

How much funding did EPRX raise in Q4 2024 and what is the runway?

EPRX raised C$44.5 million through a private placement in Q4 2024, extending funding runway into Q3 2026.

What were the latest results from EPRX's RESOLVE trial for EP-104GI?

The sixth cohort showed positive 12-week data with no adverse events and improved patient responses at higher dosing levels for eosinophilic esophagitis treatment.

How might the new U.S.-Canada tariffs affect EPRX's operations?

EPRX sources API and manufactures clinical supplies in the U.S., making it potentially vulnerable to the proposed 25% tariffs and retaliatory measures between U.S. and Canada.